{
  "schema_version": "1.3.1",
  "doc": {
    "doc_id": "133b3825a8c482f4c5ec570b284dff03",
    "title": "Jefferies",
    "source_uri": "2025-08-30/Vaccine Weekly Tracker Policy Regulation Rx CV19 Flu PCV RSV Vaccine Weekly Tracker Policy Regulation Rx CV19 Flu PCV RS_2025-08-30",
    "language": "en",
    "timestamps": {
      "ingested_at": "2025-10-27T00:45:17.855882",
      "extracted_at": "2025-10-27T00:45:17.855894"
    },
    "extraction_run": {
      "vision_model": "deepseek-ai/DeepSeek-OCR",
      "synthesis_model": "rule-based-engine",
      "pipeline_steps": [
        "ocr",
        "rule_extraction",
        "figure_vision"
      ],
      "processing_metadata": {
        "pages_processed": 15,
        "successful_pages": 15,
        "date": "2025-08-30",
        "publication": "2025-08-30",
        "authors": [],
        "markdown_cleaning": {
          "removed_sections": 2,
          "removed_paragraphs": 10,
          "reduction_ratio": 0.14311749712761324
        },
        "input_relative_path": "2025-08-30"
      }
    }
  },
  "passages": [
    {
      "passage_id": "e6f3f5207342c470",
      "text": "NORTH AMERICA | Biotechnology",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "81bb302e91623590",
      "text": "Vaccine Weekly Tracker policy/ Regulation + Rx (CV19, Flu, PCV, RSV)",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "ac82dea4ca1a9475",
      "text": "Policy watch: CDC crisis, FDA finalizes CV19 BLAs, CV19 wastewater levels rise, critical Sept 18- 19 ACIP meeting. Retail Rx from key respiratory vaccines as of 8/22. The '24- '25 respiratory season has closed, reaching \\(\\sim 30.7M\\) CV19 / \\(\\sim 78M\\) Flu total scripts. The new '25- '26 respiratory season starting w/ 974k Flu scripts, \\(+55\\%\\) w/w, and 83k CV19 scripts, \\(- 20\\%\\) w/w. The '25- '26 PCV season reached 65k scripts, \\(+15\\%\\) w/w. '25- '26 RSV season reached 50k scripts, \\(+15\\%\\) w/w.",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "9f54b8cb518ba189",
      "text": "Bottom line. As the vaccine space evolves on the policy/regulation side under new leadership, we provide our thoughts on recent landscape updates and watch for key upcoming catalysts Chart 1. This week brought unprecedented CDC turmoil with the leadership ouster of Senate- confirmed director amplifying a feeling of uncertainty ahead of the CV19 season. The CV19 BLA approvals for all vaccines (PFE/BNTX, MRNA, NVAX/SNY) gave assurance, but the upcoming Sept 18- 19 vote remains key hurdle for insurance coverage and pharmacy access. Rising CV19 wastewater levels and XFG sub- variant activity show a predicted seasonality pattern for CV19 with antigenic drift (and not complete lineage shift), favoring NVAX.",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "be9b932f21a00f67",
      "text": "1) CDC upheaval. The Senate-confirmed CDC Director, Susan Monarez, was fired 8/28 after reported clashes w/ HHS Secretary RFK Jr over vaccine policy. Following an announcement on HHS's X account, Dr. Monarez's legal team stated she had neither resigned nor received notification from White House (stating only President Trump, who appointed her, could fire her) that she has been fired. RFK Jr emailed CDC employees appointing Jim O'Neill, HHS deputy w/ no medical credentials and prev anti-vaccine statements, as Acting Director. Dr. Monarez's removal triggered resignations of other senior officials (Debra Houry, Demetre Daskalakis, Daniel Jernigan) and a staff walkout at CDC HQ. This introduces governance instability and raises concerns about scientific independence.",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "09e8ad347a51d911",
      "text": "2) CV19 BLAs are here, and EUAs are out. We view the acceptance of all four (Spikevax, NextSpike, Comirnaty, Nuvaxovid) CV19 vaccines as a hurdle now cleared, and while this approval and consistency of \"risk-based approval\" were positives amid the chaos, we still await the upcoming ACIP meeting to receive the group's recommendation on CV19 vaccine use, which is tied to insurance coverage and pharmacy access. We note the PMC requirement for PFE added a further pbo-controlled study to investigate \"circulating SARS-COV-2 spike antigen\" and \"post-COVID-19 vaccination syndrome,\" which has remained undefined/vague.",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "1d7ced0dc7c8e23b",
      "text": "3) CV19 epidemiology update. CV19 wastewater levels are highest since Sept 2024 Chart 2. We are assured by continued antigenic drift of JN.1 lineage subvariants vs radical shift, favoring NVAX's JN.1 \"tree trunk\" strategy.",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "a31a88db2879ce8b",
      "text": "See Full Report for ACIP Meeting and More.",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "a499242b5661f2aa",
      "text": "See recent Vaccine Weekly Tracker notes: 8/23, 8/16, 8/9, 8/2, 7/26, 7/19, 7/12, 7/05, 6/28, 6/21, 6/14, 6/06",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "1571c4ae2bc82fa1",
      "text": "Chart 1 - Key Upcoming Respiratory Vaccine Catalysts As of 8/29/2025",
      "page": 1,
      "section": null
    },
    {
      "passage_id": "2abcd59000bb15ae",
      "text": "EventTimePotential Impact on Vaccine TypeLevel of Impact (1-5)OutcomeKYRIA USA Decision &amp;amp; PMAC Request2025+Reaching to new COVID vaccine and COVID 25-26 seasonRIV &amp;amp; Senate Testimony14-MayBudget, QI on Vaccine PolicyVBPIRAC COVID-19 Strain Selection22-MayCOVID-19 strain selection for 25-26 seasonMIRRA COVID-19 (mRNA) 12/01/202431-MayReaching to new COVID vaccine and mRNA vaccinesVBPIRAC COVID-19 and mRNA Testimonies25COVID-19 vaccine and mRNA vaccineMIRR &amp;amp; mRNA (doxycycline) 10/04/202430-JunReaching to new COVID vaccine and mRNA vaccinesRIV &amp;amp; Change ACP Panel Membership31-JunVaccine for COVID, Vaccine Schedule for ChildrenMIRRA RIV Vaccine 18-19/01/202412-JunHIGF1A position on mRNA Vaccines in under 59MIRRA RIV + COVID-19 mRNA24-JunHIGF1A position on mRNA Vaccines in under 59ACCP COVID-19 Meeting25-JunVaccine for COVID, Vaccine Schedule for ChildrenMIRRA Spokane Full Approval +12yr7-JulFIIA continues to back risk-based mRNA vaccineCDC Director Final Confirmation25Sustain Mismatch (same FIIA) goals, create some CDC Autonomy from RIVCDC Director Final Confirmation25-AugFinal for the 2025-26 season policies, create some CDC Autonomy from RIVCDC Director Final Confirmation25-OctFollowing the 2025-26 season policies, create some CDC Autonomy from RIVFlu Vaccine Framework2025Make status as to address long-standing issues of strain selection/coverageFlu Vaccine Framework2025Make status in to address long-standing issues of strain selection/coverageVaccine Policy2025COVID-19 vaccine and mRNA vaccineVaccine Policy2025COVID vaccine and mRNA vaccineVaccine Policy2026COVID vaccine and mRNA vaccineVaccine Policy2017COVID vaccine and mRNA vaccineVaccine Policy2025COVID vaccine and mRNA vaccineVaccine Policy2017COVID vaccine and mRNA vaccineVaccine Policy2025COVID vaccine and mRNA vaccineVaccine Policy2017COVID vaccine and mRNA vaccineVaccine Policy2025COVID vaccine and mRNA vaccineVaccine Policy2017COVID vaccine and mRNA vaccineVaccine Policy2025COVID vaccine and mRNA vaccineVaccine Policy2017COVID vaccine and mRNA vaccineVaccine Policy2025COVID vaccine and mRNA vaccineVaccine Policy2017COVID vaccine and mRNA vaccineVaccine Policy2025COVID vaccine and mRNA vaccineVaccine Policy2017COVID vaccine and mRNA vaccineVaccine Policy2025COVID vaccine and mRNA vaccineVaccine Policy2017COVID vaccine and mRNA vaccineVaccine Policy2025COVID vaccine and mRNA vaccineVaccine Policy2017COVID vaccine and mRNA vaccineVaccine Policy2025COVID vaccine and mRNA vaccineVaccine Policy2017COVID vaccine and mRNA vaccineVaccine Policy2025COVID vaccine and mRNA vaccineVaccine Policy2017COVID vaccine and mRNA vaccineVaccine Policy2025COVID vaccine and mRNA vaccineVaccine Policy2017COVID vaccine and mRNA vaccineVaccine Policy2025COVID vaccine and mRNA vaccineVaccine Policy2017COVID vaccine and mRNA vaccineVaccine Policy2025COVID vaccine and mRNA vaccineVaccine Policy2017COVID vaccine and mRNA vaccineVaccine Policy2025COVID vaccine and mRNA vaccineVaccine Policy2017COVID vaccine and mRNA vaccineVaccine Policy2025COVID vaccine and mRNA vaccineVaccine Policy2017COVID vaccine and mRNA vaccineVaccine Policy2025COVID vaccine and mRNA vaccineVaccine Policy2017COVID vaccine and mRNA vaccineVaccine Policy2025COVID vaccine and mRNA vaccineVaccine Policy2017COVID vaccine and mRNA vaccineVaccine Policy2025COVID vaccine and mRNA vaccineVaccine Policy2017COVID vaccine and mRNA vaccineVaccine Policy2025COVID vaccine and mRNA vaccineVaccine Policy2017COVID vaccine and mRNA vaccineVaccine Policy2025COVID vaccine and mRNA vaccineVaccine Policy2017COVID vaccine and mRNA vaccineVaccine Policy2025COVID vaccine and mRNA vaccineVaccine Policy2017COVID vaccine and mRNA vaccineVaccine Policy2025COVID vaccine and mRNA vaccineVaccine Policy2017COVID vaccine and mRNA vaccineVaccine Policy2025COVID vaccine and mRNA vaccineVaccine Policy2017COVID vaccine and mRNA vaccineVaccine Policy2025COVID vaccine and mRNA vaccineVaccine Policy2017COVID vaccine and mRNA vaccineVaccine Policy2025COVID vaccine and mRNA vaccineVaccine Policy2017COVID vaccine and mRNA vaccineVaccine Policy2025COVID vaccine and mRNA vaccineVaccine Policy2017COVID vaccine and mRNA vaccineVaccine Policy2025COVID vaccine and mRNA vaccineVaccine Policy2017COVID vaccine and mRNA vaccineVaccine Policy2025COVID vaccine and mRNA vaccineVaccine Policy2017COVID vaccine and mRNA vaccineVaccine Policy2025COVID vaccine and mRNA vaccineVaccine Policy2017COVID vaccine and mRNA vaccineVaccine Policy2025COVID vaccine and mRNA vaccineVaccine Policy2017COVID vaccine and mRNA vaccineVaccine Policy2025COVID vaccine and mRNA vaccineVaccine Policy2017COVID vaccine and mRNA vaccineVaccine Policy2025COVID vaccine and mRNA vaccineVaccine Policy2017COVID vaccine and mRNA vaccineVaccine Policy2025COVID vaccine and mRNA vaccineVaccine Policy2017COVID vaccine and mRNA vaccineVaccine Policy2025COVID vaccine and mRNA vaccineVaccine Policy2017COVID vaccine and mRNA vaccineVaccine Policy2025COVID vaccine and mRNA vaccineVaccine Policy2017COVID vaccine and mRNA vaccineVaccine Policy2025COVID vaccine and mRNA vaccineVaccine Policy2017COVID vaccine and mRNA vaccineVaccine Policy2025COVID vaccine and mRNA vaccineVaccine Policy2017COVID vaccine and mRNA vaccineVaccine Policy2025COVID vaccine and mRNA vaccineVaccine Policy2017COVID vaccine and mRNA vaccineVaccine Policy2025COVID vaccine and mRNA vaccineVaccine Policy2017COVID vaccine and mRNA vaccineVaccine Policy2025COVID vaccine and mRNA vaccineVaccine Policy2017COVID vaccine and mRNA vaccineVaccine Policy2025COVID vaccine and mRNA vaccineVaccine Policy2017COVID vaccine and mRNA vaccineVaccine Policy2025COVID vaccine and mRNA vaccineVaccine Policy2017COVID vaccine and mRNA vaccineVaccine Policy2025COVID vaccine and mRNA vaccineVaccine Policy2017COVID vaccine and mRNA vaccineVaccine Policy2025COVID vaccine and mRNA vaccineVaccine Policy2017COVID vaccine and mRNA vaccineVaccine Policy2025COVID vaccine and mRNA vaccineVaccine Policy2017COVID vaccine and mRNA vaccineVaccine Policy2025COVID vaccine and mRNA vaccineVaccine Policy2017COVID vaccine and mRNA vaccineVaccine Policy2025COVID vaccine and mRNA vaccineVaccine Policy2017COVID vaccine and mRNA vaccineVaccine Policy2025COVID vaccine and mRNA vaccineVaccine Policy2017COVID vaccine and mRNA vaccineVaccine Policy2025COVID vaccine and mRNA vaccineVaccine Policy2017COVID vaccine and mRNA vaccineVaccine Policy2025COVID vaccine and mRNA vaccineVaccine Policy2017COVID vaccine and mRNA vaccineVaccine Policy2025COVID vaccine and mRNA vaccineVaccine Policy2017COVID vaccine and mRNA vaccineVaccine Policy2025COVID vaccine and mRNA vaccineVaccine Policy2017COVID vaccine and mRNA vaccineVaccine Policy2025COVID vaccine and mRNA vaccineVaccine Policy2017COVID vaccine and mRNA vaccineVaccine Policy2025COVID vaccine and mRNA vaccineVaccine Policy2017COVID vaccine and mRNA vaccineVaccine Policy2025COVID vaccine and mRNA vaccineVaccine Policy2017COVID vaccine and mRNA vaccineVaccine Policy2025COVID vaccine and mRNA vaccineVaccine Policy2017COVID vaccine and mRNA vaccineVaccine Policy2025COVID vaccine and mRNA vaccineVaccine Policy2017COVID vaccine and mRNA vaccineVaccine Policy2025COVID vaccine and mRNA vaccineVaccine Policy2017COVID vaccine and mRNA vaccineVaccine Policy2025COVID vaccine and mRNA vaccineVaccine Policy2017COVID vaccine and mRNA vaccineVaccine Policy2025COVID vaccine and mRNA vaccineVaccine Policy2017COVID vaccine and mRNA vaccineVaccine Policy2025COVID vaccine and mRNA vaccineVaccine Policy2017COVID vaccine and mRNA vaccineVaccine Policy2025COVID vaccine and mRNA vaccineVaccine Policy2017COVID vaccine and mRNA vaccineVaccine Policy2025COVID vaccine and mRNA vaccineVaccine Policy2017COVID vaccine and mRNA vaccineVaccine Policy2025COVID vaccine and mRNA vaccineVaccine Policy2017COVID vaccine and mRNA vaccineVaccine Policy2025COVID vaccine and mRNA vaccineVaccine Policy2017COVID vaccine and mRNA vaccineVaccine Policy2025COVID vaccine and mRNA vaccineVaccine Policy2017COVID vaccine and mRNA vaccineVaccine Policy2025COVID vaccine and mRNA vaccineVaccine Policy2017COVID vaccine and mRNA vaccineVaccine Policy2025COVID vaccine and mRNA vaccineVaccine Policy2017COVID vaccine and mRNA vaccineVaccine Policy2025COVID vaccine and mRNA vaccineVaccine Policy2017COVID vaccine and mRNA vaccineVaccine Policy2025COVID vaccine and mRNA vaccineVaccine Policy2017COVID vaccine and mRNA vaccineVaccine Policy2025COVID vaccine and mRNA vaccineVaccine Policy2017COVID vaccine and mRNA vaccineVaccine Policy2025COVID vaccine and mRNA vaccineVaccine Policy2017COVID vaccine and mRNA vaccineVaccine Policy2025COVID vaccine and mRNA vaccineVaccine Policy2017COVID vaccine and mRNA vaccineVaccine Policy2025COVID vaccine and mRNA vaccineVaccine Policy2017COVID vaccine and mRNA vaccineVaccine Policy2025COVID vaccine and mRNA vaccineVaccine Policy2017COVID vaccine and mRNA vaccineVaccine Policy2025COVID vaccine and mRNA vaccineVaccine Policy2017COVID vaccine and mRNA vaccineVaccine Policy2025COVID vaccine and mRNA vaccineVaccine Policy2017COVID vaccine and mRNA vaccineVaccine Policy2025COVID vaccine and mRNA vaccineVaccine Policy2017COVID vaccine and mRNA vaccineVaccine Policy2025COVID vaccine and mRNA vaccineVaccine Policy2017COVID vaccine and mRNA vaccineVaccine Policy2025COVID vaccine and mRNA vaccineVaccine Policy2017COVID vaccine and mRNA vaccineVaccine Policy2025COVID vaccine and mRNA vaccineVaccine Policy2017COVID vaccine and mRNA vaccineVaccine Policy2025COVID vaccine and mRNA vaccineVaccine Policy2017COVID vaccine and mRNA vaccineVaccine Policy2025COVID vaccine and mRNA vaccineVaccine Policy2017COVID vaccine and mRNA vaccineVaccine Policy2025COVID vaccine and mRNA vaccineVaccine Policy2017COVID vaccine and mRNA vaccineVaccine Policy2025COVID vaccine and mRNA vaccineVaccine Policy2017COVID vaccine and mRNA vaccineVaccine Policy2025COVID vaccine and mRNA vaccineVaccine Policy2017COVID vaccine and mRNA vaccineVaccine Policy2025COVID vaccine and mRNA vaccineVaccine Policy2017COVID vaccine and mRNA vaccineVaccine Policy2025COVID vaccine and mRNA vaccineVaccine Policy2017COVID vaccine and mRNA vaccineVaccine Policy2025COVID vaccine and mRNA vaccineVaccine Policy2017COVID vaccine and mRNA vaccineVaccine Policy2025COVID vaccine and mRNA vaccineVaccine Policy2017COVID vaccine and mRNA vaccineVaccine Policy2025COVID vaccine and mRNA vaccineVaccine Policy2017COVID vaccine and mRNA vaccineVaccine Policy2025COVID vaccine and mRNA vaccineVaccine Policy2017COVID vaccine and mRNA vaccineVaccine Policy2025COVID vaccine and mRNA vaccineVaccine Policy2017COVID vaccine and mRNA vaccineVaccine Policy2025COVID vaccine and mRNA vaccineVaccine Policy2017COVID vaccine and mRNA vaccineVaccine Policy2025COVID vaccine and mRNA vaccineVaccine Policy2017COVID vaccine and mRNA vaccineVaccine Policy2025COVID vaccine and mRNA vaccineVaccine Policy2017COVID vaccine and mRNA vaccineVaccine Policy2025COVID vaccine and mRNA vaccineVaccine Policy2017COVID vaccine and mRNA vaccineVaccine Policy2025COVID vaccine and mRNA vaccineVaccine Policy2017COVID vaccine and mRNA vaccineVaccine Policy2025COVID vaccine and mRNA vaccineVaccine Policy2017COVID vaccine and mRNA vaccineVaccine Policy2025COVID vaccine and mRNA vaccineVaccine Policy2017COVID vaccine and mRNA vaccineVaccine Policy2025COVID vaccine and mRNA vaccineVaccine Policy2017COVID vaccine and mRNA vaccineVaccine Policy2025COVID vaccine and mRNA vaccineVaccine Policy2017COVID vaccine and mRNA vaccineVaccine Policy2025COVID vaccine and mRNA vaccineVaccine Policy2017COVID vaccine and mRNA vaccineVaccine Policy2025COVID vaccine and mRNA vaccineVaccine Policy2017COVID vaccine and mRNA vaccineVaccine Policy2025COVID vaccine and mRNA vaccineVaccine Policy2017COVID vaccine and mRNA vaccineVaccine Policy2025COVID vaccine and mRNA vaccineVaccine Policy2017COVID vaccine and mRNA vaccineVaccine Policy2025COVID vaccine and mRNA vaccineVaccine Policy2017COVID vaccine and mRNA vaccineVaccine Policy2025COVID vaccine and mRNA vaccineVaccine Policy2017COVID vaccine and mRNA vaccineVaccine Policy2025COVID vaccine and mRNA vaccineVaccine Policy2017COVID vaccine and mRNA vaccineVaccine Policy2025COVID vaccine and mRNA vaccineVaccine Policy2017COVID vaccine and mRNA vaccineVaccine Policy2025COVID vaccine and mRNA vaccineVaccine Policy2017COVID vaccine and mRNA vaccineVaccine Policy2025COVID vaccine and mRNA vaccineVaccine Policy2017COVID vaccine and mRNA vaccineVaccine Policy2025COVID vaccine and mRNA vaccineVaccine Policy2017COVID vaccine and mRNA vaccineVaccine Policy2025COVID vaccine and mRNA vaccineVaccine Policy2017COVID vaccine and mRNA vaccineVaccine Policy2025COVID vaccine and mRNA vaccineVaccine Policy2017COVID vaccine and mRNA vaccineVaccine Policy2025COVID vaccine and mRNA vaccineVaccine Policy2017COVID vaccine and mRNA vaccineVaccine Policy2025COVID vaccine and mRNA vaccineVaccine Policy2017COVID vaccine and mRNA vaccineVaccine Policy2025COVID vaccine and mRNA vaccineVaccine Policy2017COVID vaccine and mRNA vaccineVaccine Policy2025COVID vaccine and mRNA vaccineVaccine Policy2017COVID vaccine and mRNA vaccineVaccine Policy2025COVID vaccine and mRNA vaccineVaccine Policy2017COVID vaccine and mRNA vaccineVaccine Policy2025COVID vaccine and mRNA vaccineVaccine Policy2017COVID vaccine and mRNA vaccineVaccine Policy2025COVID vaccine and mRNA vaccineVaccine Policy2017COVID vaccine and mRNA vaccineVaccine Policy2025COVID vaccine and mRNA vaccineVaccine Policy2017COVID vaccine and mRNA vaccineVaccine Policy2025COVID vaccine and mRNA vaccineVaccine Policy2017COVID vaccine and mRNA vaccineVaccine Policy2025COVID vaccine and mRNA vaccineVaccine Policy2017COVID vaccine and mRNA vaccineVaccine Policy2025COVID vaccine and mRNA vaccineVaccine Policy2017COVID vaccine and mRNA vaccineVaccine Policy2025COVID vaccine and mRNA vaccineVaccine Policy2017COVID vaccine and mRNA vaccineVaccine Policy2025COVID vaccine and mRNA vaccineVaccine Policy2017COVID vaccine and mRNA vaccineVaccine Policy2025COVID vaccine and mRNA vaccineVaccine Policy2017COVID vaccine and mRNA vaccineVaccine Policy2025COVID vaccine and mRNA vaccineVaccine Policy2017COVID vaccine and mRNA vaccineVaccine Policy2025COVID vaccine and mRNA vaccineVaccine Policy2017COVID vaccine and mRNA vaccineVaccine Policy2025COVID vaccine and mRNA vaccineVaccine Policy2017COVID vaccine and mRNA vaccineVaccine Policy2025COVID vaccine and mRNA vaccineVaccine Policy2017COVID vaccine and mRNA vaccineVaccine Policy2025COVID vaccine and mRNA vaccineVaccine Policy2017COVID vaccine and mRNA vaccineVaccine Policy2025COVID vaccine and mRNA vaccineVaccine Policy2017COVID vaccine and mRNA vaccineVaccine Policy2025COVID vaccine and mRNA vaccineVaccine Policy2017COVID vaccine and mRNA vaccineVaccine Policy2025COVID vaccine and mRNA vaccineVaccine Policy2017COVID vaccine and mRNA vaccineVaccine Policy2025COVID vaccine and mRNA vaccineVaccine Policy2017COVID vaccine and mRNA vaccineVaccine Policy2025COVID vaccine and mRNA vaccineVaccine Policy2017COVID vaccine and mRNA vaccineVaccine Policy2025COVID vaccine and mRNA vaccineVaccine Policy2017COVID vaccine and mRNA vaccineVaccine Policy2025COVID vaccine and mRNA vaccineVaccine Policy2017COVID vaccine and mRNA vaccineVaccine Policy2025COVID vaccine and mRNA vaccineVaccine Policy201",
      "page": 1,
      "section": null
    },
    {
      "passage_id": "a98e6302040432dd",
      "text": "Chart 4 - US Weekly Vaccination TRx Chart (IQVIA) - CV19, Flu, RSV, & PCV As of 8/22/2025",
      "page": 2,
      "section": null
    },
    {
      "passage_id": "df199b0036902a78",
      "text": "Source: Jefferies research and IQVIA Data represents weekly TRx (scripts/prescriptions) for all available CV19 vaccines (Comirnaty, NVAx's CV19 vaccine, Spikevax), all available PCV vaccines (Capvaxive, Pneumovax 23, Prevar 13, Prevar 20, Vaxneuvance), all available RSV vaccines and monoclonal antibodies (Abrysvo, Arexy, Mresvia, Beyfortus, Synagis), and available 2023 and 2024 season flu vaccines (Afluria, Afluria quad, Fluid, Fluid quadvalent, Fluid triv, Fluvax quad, Fluvax trivalent, Flubok quad, Flubok trivalent, Flucelvax, Flucelvax Quadval, Flucelvax trival, Flulaval quadval, Flulaval trivalent, Flumist, Fluzone, Fluzone HD quad, Fluzone HD, Vaxneuvance)",
      "page": 2,
      "section": null
    },
    {
      "passage_id": "6336c7f26c276008",
      "text": "We are tracking real- time weekly Flu scripts by total Flu vaccinations and break down uptake of flu vaccinations by brand since late Aug '23.",
      "page": 2,
      "section": null
    },
    {
      "passage_id": "b9b53426f4fe73f1",
      "text": "Chart 5 - US Weekly Flu Vaccination TRx by Product (IQVIA) As of 8/22/2025",
      "page": 2,
      "section": null
    },
    {
      "passage_id": "a98010c66d758ddb",
      "text": "Source: Jefferies research and IQVIA Data represents weekly TRx (scripts/prescriptions) by product. Note: we only include the top 7 most administered flu products for the 2024 season in this plot",
      "page": 2,
      "section": null
    },
    {
      "passage_id": "eaec8d039da1bf15",
      "text": "Chart 6 - US Total Weekly Flu Vaccination TRx (IQVIA) As of 8/22/2025",
      "page": 3,
      "section": null
    },
    {
      "passage_id": "690dd5f6f6c9ffcb",
      "text": "Source: Jefferies research and IQVIA Data represents weekly TRx (scripts/prescriptions) for available 2023 and 2024 Flu vaccines (Afluria, Aflura quad, Fluid, Fluid quadrivalent, Fluid triv, Flurax quad, Flurax trivalent, Flubok quad, Flubok trivalent, Flucelvax, Flucelvax Quadval, Flucelvax trival, Flulaval quadrival, Flulaval trivalent, Flumist, Fluzone, Fluzone HD quadri, Fluzone HD, Vaxneuvance)",
      "page": 3,
      "section": null
    },
    {
      "passage_id": "b926b11d8db94978",
      "text": "We are tracking real- time weekly PCV scripts by total PCV vaccinations and break down uptake of PCV vaccinations by product since late Aug '23.",
      "page": 3,
      "section": null
    },
    {
      "passage_id": "40c13a57fde9b376",
      "text": "Chart 7 - US Weekly PCV Vaccination TRx by Product and Brand (IQVIA) As of 8/22/2025",
      "page": 3,
      "section": null
    },
    {
      "passage_id": "9cea6935ff052901",
      "text": "Source: Jefferies research and IQVIA",
      "page": 3,
      "section": null
    },
    {
      "passage_id": "4936407486fa3858",
      "text": "Chart 8 - US Total Weekly PCV Vaccination TRx (IQVIA) As of 8/22/2025",
      "page": 4,
      "section": null
    },
    {
      "passage_id": "88efb4e6b5c08737",
      "text": "Source: Jefferies research and IQVIA Data represents weekly TRx (scripts/prescriptions) for all available 2024 Flu vaccines (Capavaxive, Pneumovax 23, Prevnar 13, Prevnar 29, Vaxnevac)",
      "page": 4,
      "section": null
    },
    {
      "passage_id": "afa34132fd57fcb2",
      "text": "We are tracking real- time weekly CV19 vaccinations by total CV19 vaccinations and break down uptake of CV19 vaccinations by brand since end of Aug '23.",
      "page": 4,
      "section": null
    },
    {
      "passage_id": "995dcb06f8be40b4",
      "text": "Chart 9 - US Weekly COVID-19 Vaccination TRx by Product and Brand (IQVIA) As of 8/22/2025",
      "page": 4,
      "section": null
    },
    {
      "passage_id": "d924429c7f6225e9",
      "text": "Source: Jefferies research and IQVIA",
      "page": 4,
      "section": null
    },
    {
      "passage_id": "3bc1c5a871f76168",
      "text": "Chart 10 - US Total Weekly COVID-19 Vaccination TRx (IQVIA) As of 8/22/2025",
      "page": 5,
      "section": null
    },
    {
      "passage_id": "27eca34d91d3aa88",
      "text": "Source: Jefferies research and IQVIA Data represents weekly TRx (scripts/prescriptions) for all available CV19 vaccines (Comirnaty, NVAX's CV19 vaccine, Spikevax)",
      "page": 5,
      "section": null
    },
    {
      "passage_id": "5ae1d737707c98c2",
      "text": "We are tracking real-time weekly RSV scripts by total RSV vaccinations and break down uptake of RSV vaccinations by product since late August 2023.",
      "page": 5,
      "section": null
    },
    {
      "passage_id": "11f46293c1ad0d5f",
      "text": "Chart 11 - US Weekly RSV Vaccination TRx by Product and Brand (IQVIA) As of 8/22/2025",
      "page": 5,
      "section": null
    },
    {
      "passage_id": "16ec36bbdab72586",
      "text": "Source: Jefferies research and IQVIA \\\\*\\\\*Beyfortus is not a vaccine; it is a monoclonal antibody for infants, with activity against RSV. One dose of Beyfortus, administered as a single intramuscular injection prior to or during RSV season, may provide protection during the RSV season. If the mother received PFE's ABRYSVO, the infant would not need Beyfortus.",
      "page": 5,
      "section": null
    },
    {
      "passage_id": "ef3e0b6e24637b6b",
      "text": "\\\\*\\\\*Synagis is not a vaccine; it is a monoclonal antibody for infants, with activity against RSV. Five doses total of Synagis are typical (1 dose per month x 5 months), administered as an intramuscular injection during RSV season.",
      "page": 5,
      "section": null
    },
    {
      "passage_id": "df70fcbcb06a849d",
      "text": "US Total Weekly RSV Vaccination TRx (IQVIA)As of 8/22/2025",
      "page": 6,
      "section": null
    },
    {
      "passage_id": "e90edadcefd1ce9f",
      "text": "Source: Jefferies research and IQVIA Data represents weekly TRx (scripts/prescriptions) for all available 2024 RSV vaccines (Abrysvo, Arexvy, Mersvia) and available monoclonal antibodies (Beyfortus and Synagis)",
      "page": 6,
      "section": null
    },
    {
      "passage_id": "ad83a988b8a6f56e",
      "text": "Policy Watch (cont.)",
      "page": 7,
      "section": null
    },
    {
      "passage_id": "901e603082e3a0ef",
      "text": "4) Sept 18-19 ACIP meeting will vote on CV19 vaccine recommendations. In addition, agenda includes updates on ACIP Workgroups and HepB, MMRV, RSV vaccine recs. Room for public comment will remain available. We view this as a highly critical meeting to watch, as it will be the final hurdle to cross for CV19 vaccine manufacturers to gain full access. Insurance coverage and pharmacy access are tied to ACIP recommendations. Ahead of the meeting, Sen. Bill Cassidy (R-LA) has already called for postponement (similarly announced before June meeting when old ACIP was disbanded). Our base case assumption is that ACIP recs will follow FDA recs, although we have previously noted that ACIP member Malone disagreed with MRNA",
      "page": 7,
      "section": null
    },
    {
      "passage_id": "d2e8ab85742ca8ca",
      "text": "For Important Disclosure information on companies recommended in this report, please visit our website at https://javatar.bluematrix.com/sellside/Disclosures.action or call 212.284.2300.",
      "page": 9,
      "section": null
    },
    {
      "passage_id": "8716577e7a080364",
      "text": "(Article 3(1)e and Article 7 of MAR) Recommendation Published Recommendation Distributed",
      "page": 9,
      "section": null
    },
    {
      "passage_id": "4204d8a6245b12b8",
      "text": "August 29, 2025 17:43 P.M. August 30, 2025 7:30 A.M.",
      "page": 9,
      "section": null
    },
    {
      "passage_id": "636204f85b60b8df",
      "text": "Jefferies is acting as financial advisor to Blueprint Medicines Corporation for Sanofi's acquisition of Blueprint Medicines Corporation. Jefferies Financial Group Inc., its affiliates or subsidiaries make a market in the securities or ADRs of AstraZeneca PLC. Jefferies Financial Group Inc., its affiliates or subsidiaries make a market in the securities or ADR of BioNTech SE.",
      "page": 9,
      "section": null
    },
    {
      "passage_id": "022ef567bcd6de24",
      "text": "Jefferies Financial Group Inc., its affiliates or subsidiaries expect to receive or intend to seek compensation for investment banking services from BioNTech SE within the next three months.",
      "page": 9,
      "section": null
    },
    {
      "passage_id": "6d6ccd1185449005",
      "text": "Within the past 12 months, Jefferies Financial Group Inc., its affiliates or subsidiaries has received compensation from investment banking services from BioNTech SE.",
      "page": 9,
      "section": null
    },
    {
      "passage_id": "1a3b0694912944eb",
      "text": "Jefferies Financial Group Inc., its affiliates or subsidiaries is acting as a manager or co- manager in the underwriting or placement of securities for BioNTech SE or one of its affiliates.",
      "page": 9,
      "section": null
    },
    {
      "passage_id": "c9aa3f5ff088ee8c",
      "text": "Jefferies Financial Group Inc., its affiliates or subsidiaries has acted as a manager or co- manager in the underwriting or placement of securities for BioNTech SE or one of its affiliates within the past twelve months.",
      "page": 9,
      "section": null
    },
    {
      "passage_id": "abca1a2192bdd4f1",
      "text": "Within the past twelve months, BioNTech SE has been a client of Jefferies Financial Group Inc., its affiliates or subsidiaries and investment banking services are being or have been provided.",
      "page": 9,
      "section": null
    },
    {
      "passage_id": "f89c9aac2112b963",
      "text": "Jefferies Financial Group Inc., its affiliates or subsidiaries expect to receive or intend to seek compensation for investment banking services from Novavax, Inc. within the next three months.",
      "page": 9,
      "section": null
    },
    {
      "passage_id": "4cab3733509bcdfa",
      "text": "Jefferies Financial Group Inc., its affiliates or subsidiaries is acting as a manager or co- manager in the underwriting or placement of securities for Novavax, Inc. or one of its affiliates.",
      "page": 9,
      "section": null
    },
    {
      "passage_id": "3861efcf4f7cb15c",
      "text": "Within the past 12 months, Jefferies Financial Group Inc., its affiliates or subsidiaries has received compensation from investment banking services from Novavax, Inc.",
      "page": 9,
      "section": null
    },
    {
      "passage_id": "fc35c13301d64b30",
      "text": "Within the past twelve months, Novavax, Inc. has been a client of Jefferies Financial Group Inc., its affiliates or subsidiaries and investment banking services are being or have been provided.",
      "page": 10,
      "section": null
    },
    {
      "passage_id": "d318962fa945f47f",
      "text": "Jefferies Financial Group Inc., its affiliates or subsidiaries has acted as a manager or co- manager in the underwriting or placement of securities for Novavax, Inc. or one of its affiliates within the past twelve months.",
      "page": 10,
      "section": null
    },
    {
      "passage_id": "f640341b902c0622",
      "text": "Jefferies Financial Group Inc., its affiliates or subsidiaries expect to receive or intend to seek compensation for investment banking services from Vaxcyte, Inc. within the next three months.",
      "page": 10,
      "section": null
    },
    {
      "passage_id": "41a687c138d91a47",
      "text": "Within the past 12 months, Jefferies Financial Group Inc., its affiliates or subsidiaries has received compensation from investment banking services from Vaxcyte, Inc.",
      "page": 10,
      "section": null
    },
    {
      "passage_id": "d55da146a1926256",
      "text": "Jefferies Financial Group Inc., its affiliates or subsidiaries is acting as a manager or co- manager in the underwriting or placement of securities for Vaxcyte, Inc. or one of its affiliates.",
      "page": 10,
      "section": null
    },
    {
      "passage_id": "f5a091bc6ea09c52",
      "text": "Within the past twelve months, Vaxcyte, Inc. has been a client of Jefferies Financial Group Inc., its affiliates or subsidiaries and investment banking services are being or have been provided.",
      "page": 10,
      "section": null
    },
    {
      "passage_id": "02eea8e1143d9b54",
      "text": "Jefferies Financial Group Inc., its affiliates or subsidiaries has acted as a manager or co- manager in the underwriting or placement of securities for Vaxcyte, Inc. or one of its affiliates within the past twelve months.",
      "page": 10,
      "section": null
    },
    {
      "passage_id": "93edd58c3953aa98",
      "text": "Jefferies International Ltd, its affiliates or subsidiaries has, or had, within the past 12 months an agreement to provide investment services to Vaxcyte, Inc. Jefferies Financial Group Inc., its affiliates or subsidiaries expect to receive or intend to seek compensation for investment banking services from Vaxart, Inc. within the next three months.",
      "page": 10,
      "section": null
    },
    {
      "passage_id": "64b3584fac2e2c0a",
      "text": "Within the past 12 months, Jefferies Financial Group Inc., its affiliates or subsidiaries has received compensation from investment banking services from Vaxart, Inc.",
      "page": 10,
      "section": null
    },
    {
      "passage_id": "491fcae4788d2d07",
      "text": "Within the past twelve months, Vaxart, Inc. has been a client of Jefferies Financial Group Inc., its affiliates or subsidiaries and investment banking services are being or have been provided.",
      "page": 10,
      "section": null
    },
    {
      "passage_id": "72f1e67282f1f5f7",
      "text": "For Important Disclosure information on companies recommended in this report, please visit our website at https://javatar.bluematrix.com/sellside/Disclosures.action or call 212.284.2300.",
      "page": 10,
      "section": null
    },
    {
      "passage_id": "645e48ab2a65ccce",
      "text": "Buy - Describes securities that we expect to provide a total return (price appreciation plus yield) of \\(15\\%\\) or more within a 12- month period. Hold - Describes securities that we expect to provide a total return (price appreciation plus yield) of plus \\(15\\%\\) or minus \\(10\\%\\) within a 12- month period. Underperform - Describes securities that we expect to provide a total return (price appreciation plus yield) of minus \\(10\\%\\) or less within a 12- month period. The expected total return (price appreciation plus yield) for Buy rated securities with an average security price consistently below \\(10\\) is \\(20\\%\\) or more within a 12- month period as these companies are typically more volatile than the overall stock market. For Hold rated securities with an average security price consistently below \\(10\\) , the expected total return (price appreciation plus yield) is plus or minus \\(20\\%\\) within a 12- month period. For Underperform rated securities with an average security price consistently below \\(10\\) , the expected total return (price appreciation plus yield) is minus \\(20\\%\\) or less within a 12- month period. NR - The investment rating and price target have been temporarily suspended. Such suspensions are in compliance with applicable regulations and/or Jefferies policies.",
      "page": 10,
      "section": null
    },
    {
      "passage_id": "cc669292d8d53d4e",
      "text": "CS - Coverage Suspended. Jefferies has suspended coverage of this company.",
      "page": 10,
      "section": null
    },
    {
      "passage_id": "0d05362614519699",
      "text": "NC - Not covered. Jefferies does not cover this company.",
      "page": 10,
      "section": null
    },
    {
      "passage_id": "149c0d17dfbd51f2",
      "text": "Restricted - Describes issuers where, in conjunction with Jefferies engagement in certain transactions, company policy or applicable securities regulations prohibit certain types of communications, including investment recommendations.",
      "page": 10,
      "section": null
    },
    {
      "passage_id": "c1bfae56f2d27b86",
      "text": "Monitor - Describes securities whose company fundamentals and financials are being monitored, and for which no financial projections or opinions on the investment merits of the company are provided.",
      "page": 10,
      "section": null
    },
    {
      "passage_id": "18458fe02de48d0e",
      "text": "Jefferies methodology for assigning ratings may include the following: market capitalization, maturity, growth/value, volatility and expected total return over the next 12 months. The price targets are based on several methodologies, which may include, but are not restricted to, analyses of market risk, growth rate, revenue stream, discounted cash flow (DCF), EBITDA, EPS, cash flow (CF), free cash flow (FCF), EV/EBITDA, P/E, PE/growth, P/CF, P/FCF, premium (discount)/average group EV/EBITDA, premium (discount)/average group P/E, sum of the parts, net asset value, dividend returns, and return on equity (ROE) over the next 12 months.",
      "page": 10,
      "section": null
    },
    {
      "passage_id": "0f16195ea9021a2f",
      "text": "Jefferies Franchise Picks include stock selections from among the best stock ideas from our equity analysts over a 12 month period. Stock selection is based on fundamental analysis and may take into account other factors such as analyst conviction, differentiated analysis, a favorable risk/reward ratio and investment themes that Jefferies analysts are recommending. Jefferies Franchise Picks will include only Buy rated stocks and the number can vary depending on analyst recommendations for inclusion. Stocks will be added as new opportunities arise and removed when the reason for inclusion changes, the stock has met its desired return, if it is no longer rated Buy and/or if it triggers a stop loss. Stocks having 120 day volatility in the bottom quartile of S&P stocks will continue to have a \\(15\\%\\) stop loss, and the remainder will have a \\(20\\%\\) stop. Franchise Picks are not intended to represent a recommended portfolio of stocks and is not sector based, but we may note where we believe a Pick falls within an investment style such as growth or value.",
      "page": 10,
      "section": null
    },
    {
      "passage_id": "009ce2973d145d49",
      "text": "- AstraZeneca PLC (AZN: \\(79.90, \\text{HOLD}) \n- BioNTech SE (BNTX:\\)100.00, BUY) \n- GSK Plc (GSK: \\$39.67, HOLD) \n- Merck & Co Inc (MRK: \\$84.12, BUY) \n- Novavax, Inc. (NVAX: \\$7.47, BUY) \n- Pfizer Inc (PFE: \\$24.76, BUY) \n- Sanofi (SNY: \\$49.48, BUY) \n- Vaxart, Inc. (VXRT: \\$0.39, BUY) \n- Vaxcyte, Inc. (PCVX: \\$30.79, BUY)",
      "page": 11,
      "section": null
    },
    {
      "passage_id": "b6900a845481018e",
      "text": "Distribution of Ratings",
      "page": 11,
      "section": null
    },
    {
      "passage_id": "79eb4edbf65958f8",
      "text": "CountPercentCountPercentCountPercentBUY210760.60%37017.56%1185.60%HOLD121234.86%1078.83%221.82%UNDERPERFORM1584.54%31.90%31.90%",
      "page": 11,
      "section": null
    },
    {
      "passage_id": "3c4d4f4ab5135fdd",
      "text": "Jefferies does busines and seeks to do busines with companies covered in its research reports, and expects to receive or intends to seek compensation for investment banking services among other activities from such companies. As a result, investors should be aware that Jefferies may have a conflict of interest that could affect the objectivity of this report. Investors should consider this report as only a single factor in making their investment decision.",
      "page": 12,
      "section": null
    },
    {
      "passage_id": "7c3c16f4e5b770de",
      "text": "Jefferies Equity Research refers to research reports produced by analysts employed by one of the following Jefferies Financial Group Inc. (Jefferies) companies",
      "page": 12,
      "section": null
    },
    {
      "passage_id": "22c84875abb7dc9a",
      "text": "United States: Jefferies LLC which is an SEC registered broker- dealer and a member of FINRA (and distributed by Jefferies Research Services, LLC, an SEC registered Investment Adviser, to clients paying separately for such research).",
      "page": 12,
      "section": null
    },
    {
      "passage_id": "6fcf3ec1dbe2d239",
      "text": "Canada: Jefferies Securities Inc., which is an investment dealer registered in each of the thirteen Canadian jurisdictions and a dealer member of the Canadian Investment Regulatory Organization, including research reports produced jointly by Jefferies Securities Inc. and another Jefferies entity (and distributed by Jefferies Securities Inc.).",
      "page": 12,
      "section": null
    },
    {
      "passage_id": "6c70249d9d813483",
      "text": "Where Jefferies Securities Inc. distributes research reports produced by Jefferies LLC, Jefferies International Limited, Jefferies (Japan) Limited, Tokyo Branch or Jefferies India Private Limited, you are advised that each of Jefferies LLC, Jefferies International Limited, Jefferies (Japan) Limited, Tokyo Branch and Jefferies India Private Limited operates as a dealer in your jurisdiction under an exemption from the dealer registration requirements contained in National Instrument 31- 103 Registration Requirements, Exemptions and Ongoing Registrant Obligations and, as such, each of Jefferies LLC, Jefferies International Limited, Jefferies (Japan) Limited, Tokyo Branch and Jefferies India Private Limited is not required to be and is not a registered dealer or adviser in your jurisdiction. You are advised that where Jefferies LLC or Jefferies International Limited prepared this research report, it was not prepared in accordance with Canadian disclosure requirements relating to research reports in Canada.",
      "page": 12,
      "section": null
    },
    {
      "passage_id": "6871e6ab0340f26a",
      "text": "United Kingdom: Jefferies International Limited, which is authorized and regulated by the Financial Conduct Authority, registered in England and Wales No. 1978621; registered office: 100 Bishopsgate, London EC2N 4JL; telephone +44 (0)20 7029 8000; facsimile +44 (0)20 7029 8010.",
      "page": 12,
      "section": null
    },
    {
      "passage_id": "1e6cad8eaa736d4e",
      "text": "Japan: Jefferies (Japan) Limited, Tokyo Branch, which is a securities company registered by the Financial Services Agency of Japan and is a member of the Japan Securities Dealers Association; located at Tokyo Midtown Hibiya 30F Hibiya Mitsui Tower, 1- 1- 2 Yurakucho, Chiyoda- ku, Tokyo 100- 0006; telephone +813 5251 6100; facsimile +813 5251 6101.",
      "page": 12,
      "section": null
    },
    {
      "passage_id": "5a19d9064aeaed24",
      "text": "Australia: Jefferies (Australia) Pty Limited (ACN 623 059 898), which holds an Australian financial services license (AFSL 504712) and is located at Level 20, 60 Martin Place, Sydney NSW 2000; telephone +61 2 9364 2800.",
      "page": 12,
      "section": null
    },
    {
      "passage_id": "6958af55bae535e6",
      "text": "Dubai: Jefferies International Limited, Dubai branch, which is licensed by the Dubai Financial Services Authority (DFSA Reference Number F007325); registered office Unit L31- 06, L31- 07, Level 31, ICD Brookfield Pace, DIFC, PO Box 121208, Dubai, UAE.",
      "page": 12,
      "section": null
    },
    {
      "passage_id": "d4c0fde5e0c2718f",
      "text": "This report was prepared by personnel who are associated with Jefferies (Jefferies Securities Inc., Jefferies International Limited, Jefferies GmbH, Jefferies Hong Kong Limited, Jefferies Singapore Limited, Jefferies (Japan) Limited, Tokyo Branch, Jefferies India Private Limited), and Jefferies (Australia) Pty Ltd; or by personnel who are associated with both Jefferies LLC and Jefferies Research Services LLC (\"JRS\"). Jefferies LLC is a US registered broker- dealer and is affiliated with JRS, which is a US registered investment adviser. JRS does not create tailored or personalized research and all research provided by JRS is impersonal. If you are paying separately for this research, it is being provided to you by JRS. Otherwise, it is being provided by Jefferies LLC. Jefferies LLC, JRS, and their affiliates are collectively referred to below as \"Jefferies\". Jefferies may seek to do business with companies covered in this research report. As a result, investors should be aware that Jefferies may have a conflict of interest that could affect the objectivity of this report. Investors should consider this report as only one of many factors in making their investment decisions. Specific conflict of interest and other disclosures that are required by FINRA, the Canadian Investment Regulatory Organization and other rules are set forth in this disclosure section.",
      "page": 12,
      "section": null
    },
    {
      "passage_id": "4f2d5561a8162cf3",
      "text": "If you are receiving this report from a non- US Jefferies entity, please note the following: Unless prohibited by the provisions of Regulation S of the U.S. Securities Act of 1933, as amended, this material is distributed in the United States by Jefferies LLC, which accepts responsibility for its contents in accordance with the provisions of Rule 15a- 6 under the US Securities Exchange Act of 1934, as amended. Transactions by or on behalf of any US person may only be effected through Jefferies LLC. In the United Kingdom and European Economic Area this report is issued and/or approved for distribution by Jefferies International Limited (\"JIL\") and/or Jefferies GmbH and is intended for use only by persons who have, or have been assessed as having, suitable professional experience and expertise, or by persons to whom it can be otherwise lawfully distributed. Jefferies LLC, JIL, Jefferies GmbH and their affiliates, may make a market or provide liquidity in the financial instruments referred to in this report; and where they do make a market, such activity is disclosed specifically in this report under \"company specific disclosures\".",
      "page": 12,
      "section": null
    },
    {
      "passage_id": "f308f054b2bebabc",
      "text": "For Canadian investors, this material is intended for use only by professional or institutional investors. None of the investments or investment services mentioned or described herein is available to other persons or to anyone in Canada who is not a permitted client as defined by National Instrument 31- 103 Registration Requirements, Exemptions and Ongoing Registrant Obligations, as applicable. This research report is a general discussion of the merits and risks of a security or securities only, and is not in any way meant to be tailored to the needs and circumstances of any recipient. The information contained herein is not, and under no circumstances is to be construed as, an offer to sell securities described herein, or solicitation of an offer to buy securities described herein, in Canada or any province or territory thereof. Any offer or sale of the securities described herein in Canada will be made only under an exemption from the requirements to file a prospectus with the relevant Canadian securities regulators, if applicable, and only by a dealer properly registered under applicable securities laws or, alternatively, pursuant to an exemption from the dealer registration requirement in the relevant province or territory of Canada in which such offer or sale is made. The information contained herein is under no circumstances to be construed as investment advice in any province or territory of Canada and is not tailored to the needs of the recipient. To the extent that the information contained herein references securities of an issuer incorporated, formed or created under the laws of Canada or a province or territory of Canada, any trades in such securities must be conducted through a dealer registered in Canada. No securities commission or similar regulatory authority in Canada has reviewed or in any way passed judgment upon this research report, the information contained herein or the merits of the securities described herein, and any representation to the contrary is an offence.",
      "page": 13,
      "section": null
    },
    {
      "passage_id": "39f48e79132c82aa",
      "text": "By providing this report, neither JRS nor any other Jefferies entity accepts any authority, discretion, or control over the management of the recipient's assets. Any action taken by the recipient of this report, based on the information in the report, is at the recipient's sole judgment and risk. The recipient must perform his or her own independent review of any prospective investment. If the recipient uses the services of Jefferies LLC (or other affiliated broker-dealers), in connection with a purchase or sale of a security that is a subject of these materials, such broker- dealer may act as principal for its own accounts or as agent for another person. Only JRS is registered with the SEC as an investment adviser, and therefore neither Jefferies LLC nor any other Jefferies affiliate has any fiduciary duty in connection with distribution of these reports.",
      "page": 13,
      "section": null
    },
    {
      "passage_id": "b8b68ea52524afd0",
      "text": "The price and value of the investments referred to herein and the income from them may fluctuate. Past performance is not a guide to future performance, future returns are not guaranteed, and a loss of original capital may occur. Fluctuations in exchange rates could have adverse effects on the value or price of, or income derived from, certain investments.",
      "page": 13,
      "section": null
    },
    {
      "passage_id": "3bccfd2b915c54d3",
      "text": "This report may contain forward looking statements that may be affected by inaccurate assumptions or by known or unknown risks, uncertainties, and other important factors. As a result, the actual results, events, performance or achievements of the financial product may be materially different from those expressed or implied in such statements.",
      "page": 13,
      "section": null
    },
    {
      "passage_id": "74c8afd175ef48e9",
      "text": "This report has been prepared independently of any issuer of securities mentioned herein and not as agent of any issuer of securities. No Equity Research personnel have authority whatsoever to make any representations or warranty on behalf of the issuer(s). Any comments or statements made herein are those of the Jefferies entity producing this report and may differ from the views of other Jefferies entities.",
      "page": 13,
      "section": null
    },
    {
      "passage_id": "112abbeeee601d95",
      "text": "This report may contain information obtained from third parties, including ratings from credit ratings agencies such as Standard & Poor's, and information derived from third- party or proprietary generative artificial intelligence (Gen AI) models. Jefferies does not guarantee the accuracy, completeness, timeliness or availability of this information, and is not responsible for any errors or omissions (negligent or otherwise), regardless of the cause, or for the results obtained from the use of such content. Neither Jefferies nor any third- party content providers, including providers of Gen AI models, give any express or implied warranties, including, but not limited to, any warranties of merchantability or fitness for a particular purpose or use. Neither Jefferies nor any third- party content provider shall be liable for any direct, indirect, incidental, exemplary, compensatory, punitive, special or consequential damages, costs, expenses, legal fees, or losses (including lost income or profits and opportunity costs) in connection with any use of their content, including ratings. Credit ratings are statements of opinions and are not statements of fact or recommendations to purchase, hold or sell securities. They do not address the suitability of securities or the suitability of securities for investment purposes, and should not be relied on as investment advice. Reproduction and distribution of third party content in any form is prohibited except with the prior written permission of the related third party.",
      "page": 14,
      "section": null
    },
    {
      "passage_id": "efb2facaa4281b8f",
      "text": "Jefferies research reports are disseminated and available electronically, and, in some cases, also in printed form. Electronic research is simultaneously made available to all clients. This report or any portion hereof may not be copied, reprinted, sold, or redistributed or disclosed by the recipient or any third party, by content scraping or extraction, automated processing, or any other form or means, without the prior written consent of Jefferies. Any unauthorized use is prohibited. Neither Jefferies nor any of its respective directors, officers or employees, is responsible for guaranteeing the financial success of any investment, or accepts any liability whatsoever for any direct, indirect or consequential damages or losses arising from any use of this report or its contents. Nothing herein shall be construed to waive any liability Jefferies has under applicable U.S. federal or state securities laws.",
      "page": 14,
      "section": null
    },
    {
      "passage_id": "0ba6fa2345e69586",
      "text": "For Important Disclosure information relating to JRS, please see https://adviserinfo.sec.gov/IAPD/Content/Common/crd_iapd_Brochure.aspx? BRCHR_VRSN_ID=483878 and https://adviserinfo.sec.gov/Firm/292142 or visit our website at https://javatar.bluematrix.com/sellside/Disclosures.action, or www.jefferies.com, or call 1.888.JEFFERIES.",
      "page": 14,
      "section": null
    }
  ],
  "entities": [
    {
      "entity_id": "e8078e362a750008",
      "name": "ACIP Meeting",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "998a00bda3b18264",
      "name": "ACIP Workgroups",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "ed9f3b876c8cf7c4",
      "name": "ACOG Reaffirms",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "2e28fdad88678075",
      "name": "Acting Director",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "d4c938fd261fbba4",
      "name": "Affordable Care",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "38efa2e9cded7911",
      "name": "American College",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "12195026261f523b",
      "name": "AstraZeneca PLC",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "55b4603113ca39e7",
      "name": "Bill Cassidy",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "7c1c768f3c4bec84",
      "name": "BioNTech SE",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "9a1f2e3d51550318",
      "name": "Biotechnology\n\nVaccine",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "64d11f9a391b72aa",
      "name": "Blueprint Medicines",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "0035808db08cf525",
      "name": "Blueprint Medicines Corporation",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "0add8902e5aba1b6",
      "name": "CDC Autonomy",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "e2e20dbd42ed3b25",
      "name": "CDC Director",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "7860a2554c61a53f",
      "name": "Canadian Investment",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "b1c32cdf9b5e6ff9",
      "name": "Catalysts As",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "2143f7a7294c80d8",
      "name": "Change ACP",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "f2eb88e2ff17288a",
      "name": "Co Inc",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "0c759b57d9ad2ce6",
      "name": "Company Specific",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "8bb7d9a681cb9e40",
      "name": "Company Valuation",
      "type": "company",
      "aliases": []
    }
  ],
  "data": {
    "figures": [
      {
        "type": "other",
        "title": null,
        "page": 3,
        "axes": {
          "x": {
            "type": "other",
            "labels": null
          },
          "y": {
            "unit": null,
            "range": {
              "min": null,
              "max": null
            }
          }
        },
        "series": [],
        "figure_id": "5194f75909a6d591",
        "provenance": {
          "page": 3
        }
      },
      {
        "type": "line",
        "title": null,
        "page": 6,
        "axes": {
          "x": {
            "type": "category",
            "labels": [
              "8/18/2023",
              "9/18/2023",
              "10/18/2023",
              "11/18/2023",
              "12/18/2023",
              "1/18/2024",
              "2/18/2024",
              "3/18/2024",
              "4/18/2024",
              "5/18/2024",
              "6/18/2024",
              "7/18/2024",
              "8/18/2024",
              "9/18/2024",
              "10/18/2024",
              "11/18/2024",
              "12/18/2024",
              "1/18/2025",
              "2/18/2025",
              "3/18/2025",
              "4/18/2025",
              "5/18/2025",
              "6/18/2025",
              "7/18/2025",
              "8/18/2025"
            ]
          },
          "y": {
            "unit": "Number of Scripts",
            "range": {
              "min": 0,
              "max": 4000000
            }
          }
        },
        "series": [
          {
            "name": "CV19 Total TRx",
            "unit": "Number of Scripts",
            "values": [
              150000,
              100000,
              3500000,
              2500000,
              1200000,
              800000,
              500000,
              200000,
              300000,
              250000,
              150000,
              100000,
              100000,
              2500000,
              2000000,
              1000000,
              600000,
              300000,
              200000,
              150000,
              150000,
              100000,
              100000,
              100000,
              150000
            ]
          }
        ],
        "figure_id": "b88463b6714646fc",
        "provenance": {
          "page": 6
        }
      },
      {
        "type": "line",
        "title": null,
        "page": 5,
        "axes": {
          "x": {
            "type": "category",
            "labels": [
              "8/18/2023",
              "9/18/2023",
              "10/18/2023",
              "11/18/2023",
              "12/18/2023",
              "1/18/2024",
              "2/18/2024",
              "3/18/2024",
              "4/18/2024",
              "5/18/2024",
              "6/18/2024",
              "7/18/2024",
              "8/18/2024",
              "9/18/2024",
              "10/18/2024",
              "11/18/2024",
              "12/18/2024",
              "1/18/2025",
              "2/18/2025",
              "3/18/2025",
              "4/18/2025",
              "5/18/2025",
              "6/18/2025",
              "7/18/2025",
              "8/18/2025"
            ]
          },
          "y": {
            "unit": "Number of Scripts",
            "range": {
              "min": 0,
              "max": 200000
            }
          }
        },
        "series": [
          {
            "name": "PCV Total TRx",
            "unit": "Number of Scripts",
            "values": [
              52000,
              118000,
              135000,
              120000,
              90000,
              58000,
              45000,
              35000,
              38000,
              42000,
              35000,
              30000,
              38000,
              80000,
              115000,
              120000,
              178000,
              85000,
              140000,
              70000,
              88000,
              75000,
              60000,
              45000,
              65000
            ]
          }
        ],
        "figure_id": "291c7e99cde05151",
        "provenance": {
          "page": 5
        }
      },
      {
        "type": "line",
        "title": null,
        "page": 5,
        "axes": {
          "x": {
            "type": "category",
            "labels": [
              "8/1/2025",
              "8/8/2025",
              "8/15/2025",
              "8/22/2025"
            ]
          },
          "y": {
            "unit": "Number of Scripts",
            "range": {
              "min": 0,
              "max": 80000
            }
          }
        },
        "series": [
          {
            "name": "PFE (CV19)",
            "unit": "Number of Scripts",
            "values": [
              46000,
              55000,
              70000,
              58000
            ]
          },
          {
            "name": "NVAX (CV19)",
            "unit": "Number of Scripts",
            "values": [
              100,
              100,
              100,
              100
            ]
          },
          {
            "name": "MRNA (CV19)",
            "unit": "Number of Scripts",
            "values": [
              24000,
              27000,
              35000,
              25000
            ]
          }
        ],
        "figure_id": "aae0921cacff9216",
        "provenance": {
          "page": 5
        }
      },
      {
        "type": "line",
        "title": null,
        "page": 3,
        "axes": {
          "x": {
            "type": "category",
            "labels": [
              "8/18/2023",
              "9/18/2023",
              "10/18/2023",
              "11/18/2023",
              "12/18/2023",
              "1/18/2024",
              "2/18/2024",
              "3/18/2024",
              "4/18/2024",
              "5/18/2024",
              "6/18/2024",
              "7/18/2024",
              "8/18/2024",
              "9/18/2024",
              "10/18/2024",
              "11/18/2024",
              "12/18/2024",
              "1/18/2025",
              "2/18/2025",
              "3/18/2025",
              "4/18/2025",
              "5/18/2025",
              "6/18/2025",
              "7/18/2025",
              "8/18/2025"
            ]
          },
          "y": {
            "unit": "M",
            "range": {
              "min": 0.0,
              "max": 9.0
            }
          }
        },
        "series": [
          {
            "name": "COVID-19",
            "unit": "M",
            "values": [
              0.1,
              1.5,
              3.5,
              2.5,
              1.5,
              1.0,
              0.5,
              0.2,
              0.1,
              0.1,
              0.1,
              0.1,
              0.1,
              1.5,
              2.6,
              1.8,
              0.8,
              0.4,
              0.2,
              0.1,
              0.1,
              0.1,
              0.1,
              0.1,
              0.1
            ]
          },
          {
            "name": "PCV",
            "unit": "M",
            "values": [
              0.1,
              0.2,
              0.3,
              0.2,
              0.1,
              0.1,
              0.1,
              0.1,
              0.1,
              0.1,
              0.1,
              0.1,
              0.1,
              0.1,
              0.2,
              0.2,
              0.1,
              0.1,
              0.1,
              0.1,
              0.1,
              0.1,
              0.1,
              0.1,
              0.1
            ]
          },
          {
            "name": "Flu",
            "unit": "M",
            "values": [
              0.6,
              4.0,
              8.3,
              6.0,
              3.0,
              1.0,
              0.5,
              0.2,
              0.1,
              0.1,
              0.1,
              0.1,
              0.1,
              4.0,
              7.2,
              4.0,
              1.5,
              0.8,
              0.4,
              0.2,
              0.1,
              0.1,
              0.1,
              0.1,
              0.8
            ]
          },
          {
            "name": "RSV",
            "unit": "M",
            "values": [
              0.1,
              0.5,
              0.7,
              0.6,
              0.5,
              0.3,
              0.2,
              0.1,
              0.1,
              0.1,
              0.1,
              0.1,
              0.1,
              0.3,
              0.5,
              0.4,
              0.3,
              0.2,
              0.1,
              0.1,
              0.1,
              0.1,
              0.1,
              0.1,
              0.1
            ]
          }
        ],
        "figure_id": "6ef1d32eb64223c9",
        "provenance": {
          "page": 3
        }
      },
      {
        "type": "line",
        "title": null,
        "page": 7,
        "axes": {
          "x": {
            "type": "category",
            "labels": [
              "8/25/2023",
              "9/25/2023",
              "10/25/2023",
              "11/25/2023",
              "12/25/2023",
              "1/25/2024",
              "2/25/2024",
              "3/25/2024",
              "4/25/2024",
              "5/25/2024",
              "6/25/2024",
              "7/25/2024",
              "8/25/2024",
              "9/25/2024",
              "10/25/2024",
              "11/25/2024",
              "12/25/2024",
              "1/25/2025",
              "2/25/2025",
              "3/25/2025",
              "4/25/2025",
              "5/25/2025",
              "6/25/2025",
              "7/25/2025"
            ]
          },
          "y": {
            "unit": "Number of Scripts",
            "range": {
              "min": 0,
              "max": 700000
            }
          }
        },
        "series": [
          {
            "name": "RSV Total TRx",
            "unit": "Number of Scripts",
            "values": [
              265000,
              520000,
              610000,
              590000,
              540000,
              320000,
              500000,
              450000,
              400000,
              250000,
              340000,
              320000,
              200000,
              150000,
              120000,
              100000,
              80000,
              70000,
              60000,
              50000,
              45000,
              40000,
              40000,
              45000,
              50000,
              60000,
              70000,
              80000,
              90000,
              100000,
              120000,
              150000,
              180000,
              210000,
              200000,
              180000,
              150000,
              120000,
              100000,
              90000,
              80000,
              70000,
              60000,
              50000,
              45000,
              40000,
              35000,
              30000,
              25000,
              20000,
              25000,
              30000,
              40000,
              50000,
              60000
            ]
          }
        ],
        "figure_id": "d3e9915ee3165847",
        "provenance": {
          "page": 7
        }
      },
      {
        "type": "line",
        "title": null,
        "page": 4,
        "axes": {
          "x": {
            "type": "category",
            "labels": [
              "8/1/2025",
              "8/2/2025",
              "8/3/2025",
              "8/4/2025",
              "8/5/2025",
              "8/6/2025",
              "8/7/2025",
              "8/8/2025",
              "8/9/2025",
              "8/10/2025",
              "8/11/2025",
              "8/12/2025",
              "8/13/2025",
              "8/14/2025",
              "8/15/2025",
              "8/16/2025",
              "8/17/2025",
              "8/18/2025",
              "8/19/2025",
              "8/20/2025",
              "8/21/2025",
              "8/22/2025"
            ]
          },
          "y": {
            "unit": "Number of Scripts",
            "range": {
              "min": 0,
              "max": 40000
            }
          }
        },
        "series": [
          {
            "name": "MRK (PNEUMOVAX 23)",
            "unit": "Number of Scripts",
            "values": [
              15700,
              16000,
              16300,
              16600,
              16900,
              17200,
              17500,
              17800,
              18100,
              18400,
              18700,
              19000,
              19300,
              19600,
              19900,
              20200,
              20500,
              20800,
              21100,
              21400,
              21700,
              22000
            ]
          },
          {
            "name": "PFE (PREVNAR 13)",
            "unit": "Number of Scripts",
            "values": [
              1000,
              1000,
              1000,
              1000,
              1000,
              1000,
              1000,
              1000,
              1000,
              1000,
              1000,
              1000,
              1000,
              1000,
              1000,
              1000,
              1000,
              1000,
              1000,
              1000,
              1000,
              1000
            ]
          },
          {
            "name": "PFE (PREVNAR 20)",
            "unit": "Number of Scripts",
            "values": [
              24500,
              25000,
              25500,
              26000,
              26500,
              27000,
              27500,
              28000,
              28500,
              29000,
              29500,
              30000,
              30500,
              31000,
              31500,
              32000,
              32500,
              33000,
              33500,
              34000,
              34500,
              35000
            ]
          },
          {
            "name": "MRK (VAXNEUVANCE 15)",
            "unit": "Number of Scripts",
            "values": [
              500,
              500,
              500,
              500,
              500,
              500,
              500,
              500,
              500,
              500,
              500,
              500,
              500,
              500,
              500,
              500,
              500,
              500,
              500,
              500,
              500,
              500
            ]
          },
          {
            "name": "MRK (CAPVAXINE)",
            "unit": "Number of Scripts",
            "values": [
              1000,
              1000,
              1000,
              1000,
              1000,
              1000,
              1000,
              1000,
              1000,
              1000,
              1000,
              1000,
              1000,
              1000,
              1000,
              1000,
              1000,
              1000,
              1000,
              1000,
              1000,
              1000
            ]
          }
        ],
        "figure_id": "8c888d590a82bbce",
        "provenance": {
          "page": 4
        }
      },
      {
        "type": "line",
        "title": null,
        "page": 4,
        "axes": {
          "x": {
            "type": "category",
            "labels": [
              "8/11/2023",
              "9/11/2023",
              "10/11/2023",
              "11/11/2023",
              "12/11/2023",
              "1/11/2024",
              "2/11/2024",
              "3/11/2024",
              "4/11/2024",
              "5/11/2024",
              "6/11/2024",
              "7/11/2024",
              "8/11/2024",
              "9/11/2024",
              "10/11/2024",
              "11/11/2024",
              "12/11/2024",
              "1/11/2025",
              "2/11/2025",
              "3/11/2025",
              "4/11/2025",
              "5/11/2025",
              "6/11/2025",
              "7/11/2025",
              "8/11/2025"
            ]
          },
          "y": {
            "unit": "Number of Scripts",
            "range": {
              "min": 0,
              "max": 9000000
            }
          }
        },
        "series": [
          {
            "name": "Number of Scripts",
            "unit": "Number of Scripts",
            "values": [
              0,
              200000,
              4000000,
              8300000,
              7000000,
              2500000,
              1000000,
              500000,
              200000,
              100000,
              50000,
              50000,
              100000,
              4000000,
              7200000,
              6000000,
              2000000,
              1000000,
              700000,
              500000,
              300000,
              100000,
              50000,
              100000,
              1000000
            ]
          }
        ],
        "figure_id": "d71a0335c2a4dba0",
        "provenance": {
          "page": 4
        }
      },
      {
        "type": "line",
        "title": null,
        "page": 6,
        "axes": {
          "x": {
            "type": "category",
            "labels": [
              "8/1/2025",
              "8/2/2025",
              "8/3/2025",
              "8/4/2025",
              "8/5/2025",
              "8/6/2025",
              "8/7/2025",
              "8/8/2025",
              "8/9/2025",
              "8/10/2025",
              "8/11/2025",
              "8/12/2025",
              "8/13/2025",
              "8/14/2025",
              "8/15/2025",
              "8/16/2025",
              "8/17/2025",
              "8/18/2025",
              "8/19/2025",
              "8/20/2025",
              "8/21/2025",
              "8/22/2025"
            ]
          },
          "y": {
            "unit": "Number of Scripts",
            "range": {
              "min": 0,
              "max": 30000
            }
          }
        },
        "series": [
          {
            "name": "PFE (ABRYSVO)",
            "unit": "Number of Scripts",
            "values": [
              13500,
              13800,
              14100,
              14400,
              14700,
              15000,
              15300,
              15600,
              15900,
              16200,
              16500,
              16800,
              17100,
              17400,
              17700,
              18000,
              18300,
              18600,
              18900,
              19200,
              19500,
              19800
            ]
          },
          {
            "name": "GSK (AREXVY)",
            "unit": "Number of Scripts",
            "values": [
              15000,
              15400,
              15800,
              16200,
              16600,
              17000,
              17400,
              17800,
              18200,
              18600,
              19000,
              19400,
              19800,
              20200,
              20600,
              21000,
              21400,
              21800,
              22200,
              22600,
              23000,
              23400
            ]
          },
          {
            "name": "AZN/PFE (BEYFORTUS)",
            "unit": "Number of Scripts",
            "values": [
              500,
              520,
              540,
              560,
              580,
              600,
              620,
              640,
              660,
              680,
              700,
              720,
              740,
              760,
              780,
              800,
              820,
              840,
              860,
              880,
              900,
              920
            ]
          },
          {
            "name": "MRNA (MRESVIA)",
            "unit": "Number of Scripts",
            "values": [
              400,
              410,
              420,
              430,
              440,
              450,
              460,
              470,
              480,
              490,
              500,
              510,
              520,
              530,
              540,
              550,
              560,
              570,
              580,
              590,
              600,
              610
            ]
          },
          {
            "name": "AZN/Sobi (SYNAGIS)",
            "unit": "Number of Scripts",
            "values": [
              300,
              305,
              310,
              315,
              320,
              325,
              330,
              335,
              340,
              345,
              350,
              355,
              360,
              365,
              370,
              375,
              380,
              385,
              390,
              395,
              400,
              405
            ]
          }
        ],
        "figure_id": "8f7746c045853b46",
        "provenance": {
          "page": 6
        }
      },
      {
        "type": "line",
        "title": null,
        "page": 3,
        "axes": {
          "x": {
            "type": "category",
            "labels": [
              "7/25/2025",
              "8/1/2025",
              "8/8/2025",
              "8/15/2025",
              "8/22/2025"
            ]
          },
          "y": {
            "unit": "Number of Scripts",
            "range": {
              "min": 0,
              "max": 70000
            }
          }
        },
        "series": [
          {
            "name": "FLUAD TRIV",
            "unit": "Number of Scripts",
            "values": [
              11500,
              15000,
              25000,
              38000,
              58000
            ]
          },
          {
            "name": "FLUARIX TRIVALENT",
            "unit": "Number of Scripts",
            "values": [
              12000,
              16000,
              28000,
              40000,
              60000
            ]
          },
          {
            "name": "FLUBLOK TRIVALENT",
            "unit": "Number of Scripts",
            "values": [
              1000,
              6000,
              15000,
              27000,
              47000
            ]
          },
          {
            "name": "FLULAVAL QUADRIVAL",
            "unit": "Number of Scripts",
            "values": [
              0,
              0,
              0,
              0,
              0
            ]
          },
          {
            "name": "FLUMIST",
            "unit": "Number of Scripts",
            "values": [
              0,
              0,
              0,
              0,
              0
            ]
          },
          {
            "name": "FLUZONE HD QUADRI",
            "unit": "Number of Scripts",
            "values": [
              0,
              0,
              0,
              0,
              0
            ]
          },
          {
            "name": "VANEUVANCE",
            "unit": "Number of Scripts",
            "values": [
              0,
              0,
              0,
              0,
              0
            ]
          }
        ],
        "figure_id": "9fc754dba4757c04",
        "provenance": {
          "page": 3
        }
      }
    ],
    "tables": [],
    "numerical_data": [
      {
        "num_id": "e1d02a5e23cb1205",
        "value": 0.606,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "d><td>Count</td><td>Percent</td><td>Count</td><td>Percent</td></tr><tr><td>BUY</td><td>2107</td><td>60.60%</td><td>370</td><td>17.56%</td><td>118</td><td>5.60%</td></tr><tr><td>HOLD</td><td>1212</td><",
        "provenance": {
          "page": 11
        }
      },
      {
        "num_id": "f6c7b596415766df",
        "value": 0.17559999999999998,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "</td><td>Count</td><td>Percent</td></tr><tr><td>BUY</td><td>2107</td><td>60.60%</td><td>370</td><td>17.56%</td><td>118</td><td>5.60%</td></tr><tr><td>HOLD</td><td>1212</td><td>34.86%</td><td>107</td><",
        "provenance": {
          "page": 11
        }
      },
      {
        "num_id": "8013bf37ec113cc8",
        "value": 0.055999999999999994,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "ent</td></tr><tr><td>BUY</td><td>2107</td><td>60.60%</td><td>370</td><td>17.56%</td><td>118</td><td>5.60%</td></tr><tr><td>HOLD</td><td>1212</td><td>34.86%</td><td>107</td><td>8.83%</td><td>22</td><td",
        "provenance": {
          "page": 11
        }
      },
      {
        "num_id": "1ee721d43f2269b1",
        "value": 0.3486,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "60%</td><td>370</td><td>17.56%</td><td>118</td><td>5.60%</td></tr><tr><td>HOLD</td><td>1212</td><td>34.86%</td><td>107</td><td>8.83%</td><td>22</td><td>1.82%</td></tr><tr><td>UNDERPERFORM</td><td>158<",
        "provenance": {
          "page": 11
        }
      },
      {
        "num_id": "6e22a64bdb73fc6a",
        "value": 0.0883,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "56%</td><td>118</td><td>5.60%</td></tr><tr><td>HOLD</td><td>1212</td><td>34.86%</td><td>107</td><td>8.83%</td><td>22</td><td>1.82%</td></tr><tr><td>UNDERPERFORM</td><td>158</td><td>4.54%</td><td>3</td",
        "provenance": {
          "page": 11
        }
      },
      {
        "num_id": "4e0077f5118de2ed",
        "value": 0.0182,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": ".60%</td></tr><tr><td>HOLD</td><td>1212</td><td>34.86%</td><td>107</td><td>8.83%</td><td>22</td><td>1.82%</td></tr><tr><td>UNDERPERFORM</td><td>158</td><td>4.54%</td><td>3</td><td>1.90%</td><td>3</td>",
        "provenance": {
          "page": 11
        }
      },
      {
        "num_id": "47aecfc7ff189cce",
        "value": 0.0454,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "td><td>107</td><td>8.83%</td><td>22</td><td>1.82%</td></tr><tr><td>UNDERPERFORM</td><td>158</td><td>4.54%</td><td>3</td><td>1.90%</td><td>3</td><td>1.90%</td></tr></table><endofsentence>",
        "provenance": {
          "page": 11
        }
      },
      {
        "num_id": "936feb164bf30372",
        "value": 0.019,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "</td><td>22</td><td>1.82%</td></tr><tr><td>UNDERPERFORM</td><td>158</td><td>4.54%</td><td>3</td><td>1.90%</td><td>3</td><td>1.90%</td></tr></table><endofsentence>",
        "provenance": {
          "page": 11
        }
      },
      {
        "num_id": "0ab54c106700a432",
        "value": 0.019,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "%</td></tr><tr><td>UNDERPERFORM</td><td>158</td><td>4.54%</td><td>3</td><td>1.90%</td><td>3</td><td>1.90%</td></tr></table><endofsentence>",
        "provenance": {
          "page": 11
        }
      },
      {
        "num_id": "7ad0de204d2929d4",
        "value": 39.67,
        "unit": "$",
        "metric_type": "currency",
        "context": "- AstraZeneca PLC (AZN: \\(79.90, \\text{HOLD}) - BioNTech SE (BNTX:\\)100.00, BUY) - GSK Plc (GSK: \\$39.67, HOLD) - Merck & Co Inc (MRK: \\$84.12, BUY) - Novavax, Inc. (NVAX: \\$7.47, BUY) - Pfizer Inc (P",
        "provenance": {
          "page": 11
        }
      },
      {
        "num_id": "f90918059758b357",
        "value": 84.12,
        "unit": "$",
        "metric_type": "currency",
        "context": "HOLD}) - BioNTech SE (BNTX:\\)100.00, BUY) - GSK Plc (GSK: \\$39.67, HOLD) - Merck & Co Inc (MRK: \\$84.12, BUY) - Novavax, Inc. (NVAX: \\$7.47, BUY) - Pfizer Inc (PFE: \\$24.76, BUY) - Sanofi (SNY: \\$49.4",
        "provenance": {
          "page": 11
        }
      },
      {
        "num_id": "442c76f3193a7874",
        "value": 7.47,
        "unit": "$",
        "metric_type": "currency",
        "context": "BUY) - GSK Plc (GSK: \\$39.67, HOLD) - Merck & Co Inc (MRK: \\$84.12, BUY) - Novavax, Inc. (NVAX: \\$7.47, BUY) - Pfizer Inc (PFE: \\$24.76, BUY) - Sanofi (SNY: \\$49.48, BUY) - Vaxart, Inc. (VXRT: \\$0.39",
        "provenance": {
          "page": 11
        }
      },
      {
        "num_id": "967c2f4a4115b915",
        "value": 24.76,
        "unit": "$",
        "metric_type": "currency",
        "context": "LD) - Merck & Co Inc (MRK: \\$84.12, BUY) - Novavax, Inc. (NVAX: \\$7.47, BUY) - Pfizer Inc (PFE: \\$24.76, BUY) - Sanofi (SNY: \\$49.48, BUY) - Vaxart, Inc. (VXRT: \\$0.39, BUY) - Vaxcyte, Inc. (PCVX: \\$3",
        "provenance": {
          "page": 11
        }
      },
      {
        "num_id": "4b1a1c7d89c596ff",
        "value": 49.48,
        "unit": "$",
        "metric_type": "currency",
        "context": "84.12, BUY) - Novavax, Inc. (NVAX: \\$7.47, BUY) - Pfizer Inc (PFE: \\$24.76, BUY) - Sanofi (SNY: \\$49.48, BUY) - Vaxart, Inc. (VXRT: \\$0.39, BUY) - Vaxcyte, Inc. (PCVX: \\$30.79, BUY) Distribution of Ra",
        "provenance": {
          "page": 11
        }
      },
      {
        "num_id": "8d051f62beb9a442",
        "value": 0.39,
        "unit": "$",
        "metric_type": "currency",
        "context": "$7.47, BUY) - Pfizer Inc (PFE: \\$24.76, BUY) - Sanofi (SNY: \\$49.48, BUY) - Vaxart, Inc. (VXRT: \\$0.39, BUY) - Vaxcyte, Inc. (PCVX: \\$30.79, BUY) Distribution of Ratings <table><tr><td></td><td>Count",
        "provenance": {
          "page": 11
        }
      },
      {
        "num_id": "a2c44c35b806a109",
        "value": 30.79,
        "unit": "$",
        "metric_type": "currency",
        "context": "76, BUY) - Sanofi (SNY: \\$49.48, BUY) - Vaxart, Inc. (VXRT: \\$0.39, BUY) - Vaxcyte, Inc. (PCVX: \\$30.79, BUY) Distribution of Ratings <table><tr><td></td><td>Count</td><td>Percent</td><td>Count</td><t",
        "provenance": {
          "page": 11
        }
      }
    ],
    "claims": [],
    "relations": [],
    "extraction_summary": {
      "figures_count": 10,
      "tables_count": 0,
      "numerical_data_count": 16,
      "passages_count": 88,
      "entities_count": 20
    }
  }
}